Amarantus Bioscience Holdings Inc (AMBS)

[WarpCore61]

More statements not supported by facts.

IOW, more than one year ago, when folks were saying that we would get MANF and PD data in 2013 and revenue soon because of orphan status, Joe Rubenfeld himself said that the MANF for PD was NOT the priority, as GC finally admitted at THIS One Med Forum conference.

You should not be surprised about the change in priority noted by GC at 12:30 of this conference.

Joseph Rubinfeld was appointed to the board of Amarantus advisors on Nov. 6, 2012, and it's clear from his remarks in the press release that the MANF orphan strategy was one of the primary reasons he was brought on as an advisor. He says nothing about MANF for PD not being a priority. The strategy to get MANF to market faster is through orphan diseases, which can help clear regulatory hurdles getting MANF to market for PD. What is unclear about this strategy? It has been discussed many times by the company.

I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously.

Source:
http://ir.stockpr.com/amarantus/company-news/detail/283/amarantus-biosciences-appoints-amgen-co-founder-dr-joseph-rubinfeld-to-advisory-board

This is the audio portion of Rubinfeld's presentation at the January 2013 OneMed Forum.

Joseph Rubinfeld - Jan 2013 OneMed Presentation

What folks were saying we could get revenue soon because of orphan status? The company, or posters on a message board? I think we both know the answer to that question... the posters. Yeah, let's hold the company accountable for the expectations of posters on a message board. That makes about as much sense as holding the founders of a company responsible for all future company actions years after the founders left the company.

Gerald didn't finally admit anything of the sort at the OneMed conference. He clearly stated the orphan strategy as early as Nov. 19, 2012 in a letter to shareholders, less than 2 weeks after Rubinfeld came on board.

Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially faster than Parkinson's, Traumatic Brain Injury or Myocardial Infarction.

Source:
http://ir.stockpr.com/amarantus/company-news/detail/353/amarantus-biosciences-issues-ceo-letter-to-shareholders

I wasn't surprised at the orphan strategy Gerald discussed at the 2014 OneMed Forum because he clearly laid out the strategy 14 months earlier. I guess some of our experts missed it.